资讯

While it may ul­ti­mate­ly be im­pos­si­ble to ver­i­fy why ex­act­ly a clin­i­cal-stage biotech would de­lay a po­ten­tial new drug ap­proval, Re­lay Ther­a­peu­tics said yes ...
Gal­der­ma’s an­nu­al push, and fund­ing do­na­tion, for breast can­cer aware­ness dur­ing Oc­to­ber this year is fo­cused on the per­son­al sto­ries of sur­vivors who’ve used ...
Less than a month af­ter ar­genx first land­ed ap­proval of the sub­cu­ta­neous ver­sion of its top drug, the Dutch biotech has notched an­oth­er win in … ...
No­vo Nordisk spelled out how it will try to catch up with the ex­tra­or­di­nary de­mand for its GLP-1 drugs, un­der­scor­ing its ra­tio­nale for its in … ...
Unit­ed­Health Group’s Op­tum is shut­ting down its vir­tu­al care busi­ness, End­points News has learned. Known as Op­tum Vir­tu­al Care, the busi­ness pro­vides on­line ur­gent ...
Sarep­ta and Roche’s con­fir­ma­to­ry study for a Duchenne gene ther­a­py failed to hit its pri­ma­ry end­point, com­pli­cat­ing plans to con­vert the drug’s la­bel in­to a … ...
Eli Lil­ly will pay up to $1.925 bil­lion in cash for weight loss drug­mak­er Ver­sa­nis, mark­ing the Big Phar­ma’s fourth ac­qui­si­tion this sum­mer af­ter deals … ...
Gene ther­a­py start­up en­Gene be­came a pub­lic biotech on Wednes­day af­ter com­plet­ing its com­bi­na­tion with For­bion Eu­ro­pean Ac­qui­si­tion, a blank check com­pa­ny ...
CatalYm has racked up $150 mil­lion in an over­sub­scribed Se­ries D to ad­vance its an­ti­body drug that neu­tral­izes GDF15 — a tar­get pre­vi­ous­ly ex­plored by oth­er … ...
Ver­tex sued the fed­er­al gov­ern­ment on Mon­day in an ef­fort to ex­pand its fer­til­i­ty sup­port pro­gram to cer­tain pa­tients tak­ing its new gene ther­a­py for … ...
French biotech Smart Im­mune has raised more than half of its rough­ly €50 mil­lion ($54 mil­lion) tar­get in an on­go­ing Se­ries A round, with an … ...
BioAge Labs has reeled in the biotech in­dus­try’s largest pri­vate fi­nanc­ing round so far in 2024 as the Cal­i­for­nia start­up goes full throt­tle on the … ...